Segall Bryant & Hamill LLC Takes Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

Segall Bryant & Hamill LLC bought a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 30,378 shares of the company’s stock, valued at approximately $832,000.

Other institutional investors also recently modified their holdings of the company. Hexagon Capital Partners LLC raised its position in Myriad Genetics by 75.3% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company’s stock worth $28,000 after purchasing an additional 491 shares during the last quarter. Innealta Capital LLC bought a new position in Myriad Genetics in the 2nd quarter worth approximately $36,000. GAMMA Investing LLC raised its position in Myriad Genetics by 34.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,620 shares of the company’s stock worth $44,000 after purchasing an additional 412 shares during the last quarter. Point72 DIFC Ltd bought a new position in Myriad Genetics in the 2nd quarter worth approximately $60,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Myriad Genetics in the 2nd quarter worth approximately $82,000. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics Price Performance

Shares of MYGN stock opened at $15.49 on Monday. Myriad Genetics, Inc. has a 12-month low of $14.72 and a 12-month high of $29.30. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -11.92 and a beta of 1.93. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average of $22.26 and a 200-day moving average of $24.49.

Analyst Ratings Changes

Several research analysts recently weighed in on MYGN shares. StockNews.com cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. TD Cowen upped their target price on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Wells Fargo & Company assumed coverage on shares of Myriad Genetics in a research report on Tuesday, August 27th. They set an “overweight” rating and a $35.00 target price for the company. JPMorgan Chase & Co. upped their target price on shares of Myriad Genetics from $17.00 to $20.00 and gave the company an “underweight” rating in a research report on Wednesday, August 7th. Finally, Scotiabank upped their target price on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Tuesday, August 13th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Myriad Genetics presently has an average rating of “Hold” and a consensus price target of $27.36.

Insider Buying and Selling

In related news, CEO Paul J. Diaz sold 15,000 shares of the company’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the completion of the transaction, the chief executive officer now directly owns 962,378 shares of the company’s stock, valued at approximately $22,067,327.54. This represents a 1.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Heinrich Dreismann sold 10,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $27.05, for a total transaction of $270,500.00. Following the sale, the director now directly owns 121,648 shares in the company, valued at $3,290,578.40. This trade represents a 7.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,012 shares of company stock valued at $1,900,485. Company insiders own 2.10% of the company’s stock.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.